Corrigendum to “Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis”[Cancer Lett. 380 (2016) 87–97]

Yun-Xin Lua,b, Huai Qiang Jua, Feng Wanga,b, Le-Zong Chena,b, Qi-Nian Wua,b, Hui Shenga, Hai-Yu Moa, Zhi-Zhong Pana,c, Dan Xiea, Tie Bang Kanga, Gong Chena,c, Jing-Ping Yuna,d,

Zhao-Lei Zenga, Rui Hua Xua,b,∗
a State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060,
China
b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China c Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China d Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China

The authors regret that incorrect images appear in Figure 3B and 4D during data arranging processes. In the published Figure 3B, the flow diagram for HCT116 cells at 24 hour after nafamostat mesilate treatment was incorrectly displayed. In the published Figure 4D, the immunoblotting bands of total-ERK and GAPDH in HCT116 and SW1116 cells were from a different experimental group. This correction does not change the conclusions of this manuscript. Now the corrected Figure 3B and 4D are as below. The authors apologize for the inconvenience.

 Corresponding author. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Nafamostat  Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

E-mail address: [email protected] (R.H. Xu). https://doi.org/10.1016/j.canlet.2019.10.001
0304-3835/©2019ElsevierB.V.Allrightsreserved.